FIELD: pharmacology.
SUBSTANCE: present invention refers to immunology and biotechnology. There is offered recovered human antibody to RG1 polypeptide. There are described versions of antibodies, including one-chain antibody, and immunoconjugate based on said antibodies. There are disclosed methods of selective cell destruction, cell inhibition, treatment of disease state, detection of disease state, detection of RG1, monitoring of clinical course of prostate cancer, prediction in a person with using antibodies and immunoconjugate.
EFFECT: application of the invention provides new antibodies to RG1 polypeptide that can find application in treating tumours with RG1 overexpression.
16 cl, 4 dwg, 1 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DNA ENCODING NEW RGI PEPTIDE | 2000 |
|
RU2283130C2 |
| METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES | 2019 |
|
RU2816847C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODIES AGAINST THE PROGRAMMED DEATH LIGAND (PD-L1) AND APPLICATION THEREOF | 2019 |
|
RU2761638C1 |
| ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
| ANTIBODY POLYPEPTIDES AND THEIR APPLICATION | 2016 |
|
RU2753677C2 |
| ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | 2016 |
|
RU2739612C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODIES AND ANALYSIS METHODS FOR FOLIC ACID 1 RECEPTOR DETECTION | 2014 |
|
RU2725825C2 |
